- The FDA granted full accelerated approval to Zymeworks’ zanidatamab for HER2-positive biliary tract cancer, its first-ever approved commercial product in the U.S.
- The pivotal HERIZON-BTC-01 trial showed a 41.3% confirmed ORR, far exceeding the sub-15% response rates seen with standard second-line chemotherapy in this indication.
- Peak U.S. sales are estimated at USD $800M–$1.2B (CAD $1.12B–$1.67B), with Zymeworks retaining North American rights and Jazz Pharmaceuticals holding Europe and Japan.
- Zymeworks holds approximately USD $420M in cash through 2029, with a critical Phase 3 gastroesophageal readout expected in H1 2027 as the next major catalyst.
Vancouver’s Zymeworks Inc. (NASDAQ: ZYME; TSX: ZYME) received full FDA approval on September 17, 2026, for zanidatamab (brand name: Ziihera) in adult patients with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) — a rare but aggressive gastrointestinal malignancy with historically limited treatment options. The approval covers the second-line-and-beyond patient population and is based on confirmed objective response rate data from the HERIZON-BTC-01 pivotal trial.
What the Trial Data Showed
The HERIZON-BTC-01 study demonstrated a confirmed objective response rate (ORR) of 41.3% in HER2-overexpressing BTC patients treated with zanidatamab, with a median duration of response of 12.9 months — a clinically meaningful result in a disease where second-line chemotherapy typically produces ORRs below 15%. The FDA granted the approval under its Accelerated Approval pathway, with a confirmatory overall survival readout expected in 2028. The agency also granted zanidatamab Breakthrough Therapy Designation, which expedited the review timeline.
The Commercial Opportunity
Biliary tract cancer, which includes cholangiocarcinoma and gallbladder cancer, affects approximately 12,000 patients annually in the United States. Roughly 20–25% of those cases are HER2-positive, yielding an addressable second-line patient pool of approximately 2,400 to 3,000 U.S. patients per year. At an anticipated annual list price of approximately USD $180,000 per patient — consistent with comparable HER2-targeted oncology agents — peak U.S. sales estimates from independent analysts range between USD $800 million and USD $1.2 billion (approximately CAD $1.12B to CAD $1.67B at the current USD/CAD rate of 1.3939), assuming label expansions into first-line and gastroesophageal indications succeed.
Zymeworks retains U.S. and Canadian commercial rights to zanidatamab; Jazz Pharmaceuticals holds rights in Europe and Japan under a licensing agreement signed in 2021. That deal included USD $325 million in upfront and near-term milestone payments, partially de-risking Zymeworks’ balance sheet ahead of commercial launch. The competitive landscape in HER2-positive BTC remains relatively uncrowded: AstraZeneca’s trastuzumab deruxtecan (Enhertu) has shown early-line activity in HER2-positive solid tumors broadly, but lacks a dedicated BTC label — giving zanidatamab a meaningful first-mover regulatory advantage in this specific indication.
Stock Reaction and Long-Term Thesis
Shares of Zymeworks surged approximately 34% on the Nasdaq following the approval announcement, with the TSX-listed shares mirroring the move in early Toronto trading. The reaction reflects both relief — the FDA’s previous Complete Response Letter (CRL) to an earlier submission had weighed on the stock for over a year — and genuine commercial excitement about a first approved product. The XBI biotech ETF gained just 0.10% on the day, meaning Zymeworks’ move was company-specific and not a sector-wide tailwind.
For long-term investors, the approval transforms Zymeworks from a clinical-stage story into a revenue-generating commercial company. The key milestones to monitor now include: the Phase 3 HERIZON-GEA-01 readout in HER2-positive gastroesophageal adenocarcinoma (expected H1 2027), the potential for a supplemental BDA application in first-line BTC, and the pace of U.S. commercial launch execution. Burn rate and cash runway will become critical metrics — Zymeworks reported approximately USD $420 million in cash as of Q2 2026, which management believes funds operations into 2029.
| Metric | Detail |
|---|---|
| Drug / Brand Name | Zanidatamab / Ziihera |
| Indication | 2L+ HER2-positive biliary tract cancer |
| Regulatory Outcome | Full FDA Approval (Accelerated) |
| Pivotal Trial ORR | 41.3% confirmed ORR |
| U.S. Addressable Patients/Year | ~2,400–3,000 |
| Peak Sales Estimate | USD $800M–$1.2B (CAD $1.12B–$1.67B) |
| Jazz Pharma License Territory | Europe, Japan |
| Cash Runway (as of Q2 2026) | ~USD $420M (into 2029) |
